Dr. Renuka Iyer

Renuka Iyer

MD

Specializing In:

Bile duct cancer Cholangiocarcinoma Hepatocellular cancer Neuroendocrine cancer

Special Interests:

Develop novel therapies for rare cancer Immunotherapy


Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Professor of Oncology
  • Co-Director, Liver and Pancreas Tumor Center
  • Section Chief for Gastrointestinal Oncology
Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo
  • Professor of Medicine

Background

Education and Training:

  • 1998 - MD - Grant Medical College, University of Mumbai, Maharashtra, India

Residency:

  • 1998-2001 - Resident - Internal Medicine, Lincoln Medical and Mental Health Center and Cornell University School of Medicine, Bronx, NY
  • 1997-1998 - Postdoctoral Associate- Fox Chase Cancer Center, Philadelphia, PA

Fellowship:

  • 2001-2004 - Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY

Board Certification:

  • Internal Medicine, American Board of Internal Medicine
  • Medical Oncology, American Board of Internal Medicine

Professional Memberships:

  • Cholangiocarcinoma Foundation
  • Cholangiocarcinoma Foundation - Medical Advisory Board
  • Cholangiocarcinoma Foundation - Nursing Advisory Board
  • NANETs
  • NANETs - Regional Conference Committee Chair
  • Hepatobiliary Cancer Panel, National Comprehensive Cancer Network
  • American Association for Cancer Research
  • Carcinoid.org NET Physician/Expert
  • American Association for the Study of Liver Diseases
  • American College of Gastroenterology
  • American College of Surgeons Oncology Group
  • American Society of Clinical Oncology

Honors & Awards

  • June 2018- Best Teacher Award, Awarded by Roswell Park Cancer Institute Medical Oncology Fellows
  • June 2008 - Best Teacher Award, Awarded by Roswell Park Cancer Institute Medical Oncology Fellows
  • January 2008 - American Cancer Society Scholar Award
  • November 2007 - EORTC-NCI-ASCO Molecular Markers Development Workshop, Brussels, Belgium
  • April 2003 - Thomas Frawley Resident Research Fellowship award, by SUNY at Buffalo
  • July 2002 - ASCO-AACR Methods in Clinical Cancer Research Workshop, Vail, CO
  • October 1997 - Junior Investigator Award by the Executive Committee of the Tenth International Conference on Chemical Modifiers in Cancer Treatment

Research

Research Overview:

Research interests in phase 1 and 2 clinical trials in GI cancer and animal models research of liver cancer.


Publications

Full Publications list on PubMed
  • S Kalathil, A Lugade, A Miller, RV Iyer, Y Thanavala: PD-1+ and Roxp3+ T cell reduction correlates with survival of HCC patients after sorafenib therapy. JCI Insight. 2016;1(11)
  • S Kalathil, A Lugade, R Iyer, Y Thanavala: Endothelial progenitor cell number and ERK phosphorylation serve as predictive and prognostic biomarkers in advanced hepatocellular carcinoma patients treated with sorafenib. OncoImmunology 5(10):00-00 · September 2016
  • Suresh Kalathil, Amit A. Lugade, Austin Miller, Renuka Iyer and Yasmin Thanavala: Higher Frequencies of GARP+CTLA-4+Foxp3+ T Regulatory Cells and Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Are Associated with Impaired